~8.1× EV/EBITDA (FY26E) · EV/S 1.15× · ~13% FCF yield · 3.9% dividend — cheap vs the market, typical for the sector
Exponential Potential
3/10 · Low — ~3.9% organic growth; the revenue jump is acquired (IPG), not organic acceleration; AI is a threat to the model
Technicals
Rangebound/soft — $78.62, −8% off 52-wk high, ~flat to 50/200-DMA, RSI 58, +6.5% 12-mo vs SPY +20.6% (lagging)
Conviction
None — 0 expert voices, 0 claims in the Synthos KB. This is a quant/fundamentals call only
Position sizing
If owned at all: small ~1–2% value/income sleeve, not a core or growth holding
Next catalyst
2026-07-21 Q2'26 earnings (Street EPS $2.64, revenue ~$6.45B) — first full look at IPG synergy execution
Single biggest risk
Generative AI disintermediating the agency value chain (media buying, creative, production) faster than Omnicom can reposition
One-line thesis. Omnicom just doubled its size by absorbing rival Interpublic (IPG, closed Nov 26 2025), and the combined entity is genuinely cheap (~8× EV/EBITDA, ~13% FCF yield, near-4% dividend) with real synergy upside — but organic growth is only ~3.9%, the balance sheet took on meaningful merger debt, and the entire advertising-agency model faces an unresolved generative-AI question. That combination is a Watch, not a buy: a value/income name to monitor for synergy proof and organic re-acceleration, not a compounder.
◆ Synthos call — HoldOMC is a solid business largely reflected at ~$89 — fine to keep, no reason to chase; it gets interesting again below ~$76.
Downside Risk (lower = safer)
6/10 · High
Cheap (8× EV/EBITDA) & low beta 0.66, but 4.5× net-debt/EBITDA post-IPG, −25% max drawdown, and a secular AI threat to the whole agency model.
Growth Quality
4/10 · Moderate
Only ~3.9% organic growth; the top-line jump is bought (IPG), not earned; net margin razor-thin GAAP and merger-charge-distorted.
Exponential Potential
3/10 · Low
Mature, low-single-digit-organic advertising holdco; the deal adds scale, not acceleration — AI is a headwind, not a tailwind.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 4%/yrTo justify today’s $79, earnings would have to compound roughly 4% a year for 10 years (9% discount rate). Analysts forecast ~12%/yr, so the market is pricing in LESS than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Omnicom is one of the world's biggest advertising and marketing holding companies — it owns the agencies that make ads, buy TV/digital ad space, run PR, and handle marketing for large brands. In late 2025 it bought its big rival Interpublic (IPG), so the company you see today is roughly twice the size it was a year ago.
Is the stock cheap or expensive? Cheap — you pay about 8 dollars for every dollar of yearly cash earnings (the overall market pays roughly double that), it throws off a lot of cash, and it pays a ~3.9% dividend. The catch is why it's cheap: the business barely grows on its own (about 4% a year), and investors worry that AI could do a lot of what ad agencies do — write copy, make images, buy media — which would shrink the whole industry.
Our verdict is Watch: not a bargain to rush into, not a disaster to avoid — a "prove it" stock. We want to see the IPG merger actually deliver the promised cost savings and the underlying business start growing faster before calling it a buy.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit elevated). The stock is cheap and doesn't swing wildly, but the company took on a chunk of debt to buy IPG, the shares have already fallen ~25% from their peak, and AI is a real long-term threat.
Growth Quality 4/10 (below average). It grows slowly on its own; the big size jump was bought, not earned, and the true profit picture is muddied by one-time merger costs.
Exponential Potential 3/10 (low). This is a mature, slow-growth business. Buying a rival adds scale but not speed, and AI is more headwind than tailwind here.
The one big worry: generative AI could hollow out the traditional agency business faster than Omnicom can adapt.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLC (sector)), set to 100 a year ago
Solid = OMC · dashed = S&P 500 · dotted = XLC (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$78.62
Market cap$22B
P/E trailing3×
P/E FY26E / FY27E7× / 7×
EV / Sales1.5×
EV / EBITDA25.9×
Gross margin16.8%
Net margin0.3%
Dividend yield3.94%
Beta0.659
52-wk range$67 – $86
RSI(14)58
50 / 200-DMA$75 / $76
12-mo return+6% (SPY +21%)
Street target$106 ($83–$146)
Analyst grades11 Buy · 20 Hold · 3 Sell
FMP ratingB-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on OMC · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Omnicom Group (NYSE: OMC), founded 1944, is one of the "big four" global advertising and marketing holding companies. It owns networks of agencies spanning media planning and buying, creative advertising, public relations, healthcare communications, precision/CRM marketing, and experiential. Its clients are the world's largest brands; its revenue is essentially a slice of global marketing spend. Fiscal year ends December 31. CEO John Wren has run the company for decades.
The defining event: on November 26, 2025, Omnicom closed its acquisition of The Interpublic Group (IPG) — a combination of the #3 and #4 global agency holdcos. Q1'26 is the first full quarter reflecting the merged entity, and it explains nearly every large year-over-year distortion in the financials (revenue, share count, debt, goodwill, and a large FY25 merger-charge net loss). Management brands the combined company "the new Omnicom," built around "the largest global media platform" and an AI-powered "Omni" data/identity platform.
Revenue mix (FY2025 reported, pre-full-IPG-consolidation — from filings):
By discipline: Advertising $10.02B (58%) · Public Relations $1.61B · Health Care $1.38B · Experiential $0.86B. (In the Q1'26 release, on a combined "Core Operations" basis, the mix shifts to: Integrated Media ~51.5%, Advertising 16.8%, Public Relations 11.7%, Experiential/Other 10.4%, Health 9.5% — media buying is now the single largest discipline.)
By geography (FY2025): North America $9.59B + United States line $9.10B (dominant) · EMEA $4.80B · Asia Pacific $1.93B · Latin America $0.54B · Middle East & Africa $0.41B. In the Q1'26 combined view the United States is ~61% of revenue — a US-concentrated base.
2. The expert thesis
There is no expert coverage of OMC in the Synthos knowledge base.total_claims = 0, net_bullish_voices = 0. None of the tracked expert voices (the panel that drives our conviction-track names) has an on-record, traceable claim on Omnicom.
What this means for the verdict, stated plainly: this deep dive is fundamentals- and quant-driven only. There is no independent expert conviction to lean on, and we do not manufacture any. Where a conviction name like a GLP-1 leader earns a High rating from a broad, reconciled expert panel, OMC earns its rating solely from the numbers, the Street consensus (a Hold), and the structural read below. Absence of coverage is itself information: this is not a name the highest-signal investors we track are championing.
3. Synthos scores & the Bull / Base / Bear cases
Three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Elevated-moderate
Positives: cheap (~8× EV/EBITDA), low beta (0.66), fat FCF, covered dividend. Negatives: net-debt/EBITDA rose to ~1.6× on FY26E EBITDA (and ~4.5× on the merger-distorted FY25 reported EBITDA), shares already −25% from peak, and a genuine secular AI threat to the model.
Growth Quality
4 · Below average
Organic growth just ~3.9% (Q1'26); the headline revenue doubling is bought (IPG), not earned. GAAP net margin is razor-thin and merger-charge-distorted; adjusted EBITA margin ~14.8% is respectable but not expanding organically.
Exponential Potential
3 · Low
A mature, low-single-digit-organic advertising holdco. The deal adds scale and cost synergies, not growth acceleration. AI is more headwind than tailwind. A decelerating, no-acceleration profile.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. Because the FMP GAAP-EPS estimates appear to be struck on a pre-IPG share count (see §6), we anchor the cases on the company's normalized post-merger Non-GAAP adjusted EPS (~$8.5 combined run-rate implied by Q1'26 adj. EPS of $1.90 plus a synergy ramp) and a sector-appropriate multiple — a more honest basis than a distorted GAAP number.
Case
Key assumptions
Fair value
Bull
IPG synergies land in full ($750M+ target), organic growth re-accelerates toward mid-single digits, buyback ($3.5B this year) shrinks the share count fast; normalized adj. EPS ~$9.0, multiple re-rates to ~12× as AI fears fade.
~$108 (+37%)
Base(our anchor)
Merger integrates on plan but organic stays low-single-digit; normalized adj. EPS ~$8.5; sector multiple ~10.5× (a modest discount for AI overhang).
~$89 (+13%)
Bear
AI accelerates client budget/agency disintermediation, synergies slip, integration friction hits organic growth; adj. EPS ~$7.5; multiple de-rates to ~8×.
~$60 (−24%)
Synthos fair value = the base case, ~$89 (+13%), with the full $60–$108 span as the honest range. Our base sits below the Street's $106.33 consensus: we give less benefit of the doubt on the synergy/organic-growth combination and apply a structural AI discount to the multiple. Note the Street's own signal is only a Hold (11 Buy / 20 Hold / 3 Sell). This is a tracked call.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). OMC is neither — it is a mature, cyclical, low-growth holding company:
Forward growth is scale-bought, not organic. The FY25→FY26E revenue jump (to ~$25.8B consensus) is almost entirely the IPG consolidation, not demand. Underlying organic growth is ~3.9% (Q1'26, company-reported).
Acceleration (the 2nd derivative) is roughly flat-to-negative. Ex-merger, this is a low-single-digit-organic business tied to global ad spend and GDP. There is no inflection; if anything, generative AI threatens to compress the agency take-rate over time.
Room to run is not the constraint — the TAM is mature. Global advertising is a large but slow-growing, cyclical pool. Consolidating two of the four majors buys market share and cost leverage, but the combined entity is more exposed to any structural shrinkage of the agency layer, not less.
Reinvestment is via M&A and buybacks, not organic reinvestment at high ROIC. ROIC is modest (~4% TTM on a merger-distorted base; return on capital employed ~11%). Capital return (dividend + $5.0B buyback authorization) is the shareholder story, not compounding growth.
Exponential Potential: Low (3/10). Own OMC, if at all, for cash return and a cheap multiple, explicitly not for growth or optionality. This is the opposite profile from a forward-exponential.
Read the merger distortion first. Nearly every FY2025 and YoY figure is warped by the IPG deal closing Nov 26 2025. FY2025 as reported shows a net loss of −$54.5M and negative Q4'25 EBITDA — driven by ~$1.9B of non-operating/deal-related charges in Q4, not operating deterioration. Use adjusted/core operations figures for the real trend.
Revenue: FY25 reported $17.27B (+10.1% on FY24 $15.69B — only ~5 weeks of IPG). Q1'26 $6.24B (includes a full quarter of IPG). Combined "Core Operations" Q1'26 revenue $5.6B, +3.9% organic.
Profitability (adjusted, the meaningful line): Q1'26 Non-GAAP adjusted EBITA $861.4M, 13.8% margin (Core Operations margin 14.8%, up from 12.4% — cost synergies). Q1'26 Non-GAAP adjusted diluted EPS $1.90, +11.8% YoY; GAAP diluted EPS $1.35 (down YoY on merger costs and dilution).
GAAP earnings: FY25 net loss −$54.5M (merger charges); Q1'26 GAAP net income $405.2M. The gap between GAAP and adjusted is almost entirely IPG amortization + integration costs.
Cash flow (the real strength): FY25 operating CF $2.94B, capex only −$150M, FCF $2.79B → a ~13% FCF yield on the current market cap. FCF is the anchor of the value case (asset-light, low-capex model).
Balance sheet: post-IPG, total debt $12.78B, cash $6.88B, net debt $5.90B. Net-debt/EBITDA is ~1.6× on FY26E EBITDA (~$3.68B) — manageable — but ~4.5–6× on the merger-distorted FY25 reported EBITDA; the leverage picture normalizes only as combined EBITDA is fully reflected. Goodwill + intangibles ballooned to $23.7B (from $11.2B) — the price of the deal, and a future impairment risk if synergies disappoint.
Share count (critical): weighted-average diluted shares jumped to 299.2M in Q1'26 (from 198.3M) — IPG was an all-stock deal. This is why per-share GAAP figures fell even as absolute profit rose.
6. Valuation — cheap for a reason
On cash and enterprise metrics OMC is unambiguously cheap: ~8.1× EV/EBITDA (FY26E), 1.15× EV/sales, ~13% FCF yield, 3.9% dividend yield (payout well-covered by FCF; TTM GAAP payout ratio is meaningless given the merger loss). FMP letter rating B-; P/B 1.7×.
Important data caveat (honesty first): the FMP forward GAAP EPS estimates — $10.50 (FY26E) rising to $16.54 (FY30E) — appear to be struck on a pre-IPG ~205M share count, not the post-merger ~299M diluted count (marketCap ÷ price ≈ 285M shares; Q1'26 diluted 299.2M). Backing $10.50 out of FY26E net income (~$2.15B) implies ~205M shares. On the correct ~285–299M share base, GAAP EPS is closer to ~$7.2–7.6, and the "$16.54 by 2030" figure is overstated. We therefore do not anchor on those EPS estimates or on the "$16.54 × multiple" math; we anchor on EV/EBITDA, FCF, and the company's own Non-GAAP adjusted EPS (~$8.5 normalized), which are struck on the real combined entity. Treat all FMP per-share forward estimates for OMC as suspect until they re-base.
Street targets (context): consensus $106.33, high $146, low $83, median $90. The wide spread and Hold consensus reflect exactly the tension here — cheap cash flows vs. an unresolved growth/AI question. Our ~$89 base FV is below consensus and closer to the Street median ($90), reflecting a deliberate structural discount. Not a value trap by the numbers, but not a name where the multiple obviously re-rates without organic proof.
7. Technicals (from the tech block)
Trend:soft/rangebound. $78.62 sits just above the 50-DMA ($74.98) but roughly at/above the 200-DMA ($76.45) — no clean uptrend, no golden-cross momentum. MACD marginally positive (+0.10).
Location:−8.4% off the 52-week high ($85.80), +16.9% off the 52-week low ($67.27) — mid-range. Notably, max drawdown from peak was −25.5% — this stock has already had a real correction (the IPG deal + AI fears).
Momentum: RSI(14) 58 — neutral, neither overbought nor oversold.
Relative strength (the tell — it's weak): OMC +6.5% 12-mo vs SPY +20.6% and QQQ +30.3% — material underperformance of both the market and tech. 6-mo return is negative (−2.6%) while SPY is +8.4%. This is a laggard, not a leader.
Read: technicals confirm the fundamental caution — no trend, persistent underperformance. There is no technical urgency to own it; a value buyer would want it nearer the low-$70s / 52-wk-low zone for margin of safety.
8. Moat & competitive position
Omnicom's moat is scale, entrenched global client relationships, and a media-buying data platform — real but eroding advantages. The traditional agency moat (creative talent + media-buying leverage) is precisely what generative AI threatens to commoditize. The IPG merger is defensive as much as offensive: consolidating to defend media-buying scale and spread technology (the "Omni" platform) costs across a bigger base. The company is now the largest agency holdco by revenue, ahead of Publicis and WPP.
Peer set (FMP-provided, market cap): IPG (now being absorbed) $8.9B, WPP plc $3.6B (a struggling direct global peer), and a grab-bag of communication-services names FMP lists as comparables — Roku $21.1B, Snap $8.2B, Warner Music $14.8B, News Corp $15.0B, TKO Group $14.6B, TIM S.A. $10.4B, Lumen $6.6B. (Note: several of these are not clean agency comps — the cleanest public peers are WPP and Publicis. WPP's own de-rating is a warning: the market is pricing structural pressure across the whole traditional-agency group.)
9. Management, capital allocation & guidance
Capital allocation: clear and shareholder-friendly on the surface — a $5.0B buyback authorization with $3.5B targeted for 2026, a ~3.9% dividend covered by FCF, and the IPG deal funded largely with stock (limiting cash outlay but diluting holders ~50%). The bet is that cost synergies + buyback drive per-share value even with slow organic growth.
Insider activity: the recent Form 4s (May 2026) for CEO John Wren, Co-President Daryl Simm, and CFO Philip Angelastro are routine equity awards (A-Award) and tax-withholding in-kind dispositions (F-InKind at $70.83–$74.93) — compensation mechanics, not open-market discretionary selling. No alarming signal, but no conviction insider buying either.
Management's own guidance (half-weighted — their own book): the SEC 8-K Q1'26 earnings release (2026-04-28) is a real earnings release and states management's forward posture in their own words: on track to achieve "substantial cost reduction synergies" and "$3.5 billion in share repurchases this year under our $5.0 billion authorization," with CEO Wren claiming the combination "will set a new standard for our sector" on profitability and EPS growth. This is self-interested framing (weight accordingly): it emphasizes synergies and buybacks — the levers management controls — and is quieter on organic growth acceleration, which is the real open question. No specific full-year revenue/EPS numeric guidance was captured in the release text.
10. Catalysts & what to watch
Next earnings: 2026-07-21 (Q2'26; Street EPS $2.64, revenue ~$6.45B). The key lines: organic growth (is it holding ~4%?) and adjusted EBITA margin (are synergies showing?).
IPG synergy realization: hard evidence of the promised cost savings flowing to margin — the central bull lever.
Buyback pace: confirmation of the $3.5B repurchase shrinking the newly enlarged share count.
Organic re-acceleration vs. AI erosion: any sign the combined book is growing (bull) or that clients are shifting spend to AI-native/in-house tools (bear).
Goodwill/intangibles: watch for any impairment flag on the $23.7B carried — a synergy shortfall would surface here.
FMP estimate re-basing: watch for the forward per-share estimates to re-cut onto the ~299M share count (currently stale).
Thesis tripwires (what would change the call): organic growth turning negative; adjusted EBITA margin failing to expand as synergies were promised; a goodwill impairment; or the buyback being curtailed to service debt.
11. Key risks
Secular AI disruption (structural, the big one): generative AI can increasingly automate creative production, copy, and even media planning/buying — threatening the core agency value proposition and take-rate. This is the reason the whole group trades cheap.
Integration risk: merging the #3 and #4 holdcos is operationally hard — client conflicts, talent flight, culture clash, and synergy slippage are all live. Roughly 50% share dilution raises the bar for per-share accretion.
Cyclicality: advertising spend is pro-cyclical; a recession cuts marketing budgets fast.
Leverage & goodwill: net debt $5.9B and $23.7B of goodwill/intangibles leave impairment and balance-sheet risk if synergies disappoint.
US/client concentration: ~61% US revenue and large-brand client concentration expose it to US macro and a few big accounts.
No expert conviction: the Synthos KB has zero coverage — no independent high-signal voice is underwriting a bull case here.
12. Verdict, position sizing & monitoring
Watch. Omnicom is a genuinely cheap, cash-generative, dividend-paying business (~8× EV/EBITDA, ~13% FCF yield, 3.9% yield) that just made a transformational, share-diluting acquisition into an industry facing a real secular AI question. That is the textbook definition of a Watch: the value is real, but so are the reasons for the discount, and there is no expert conviction and only a Street Hold to lean on. We want proof — synergy realization and organic re-acceleration — before it becomes a buy.
Sizing: if owned at all, a small ~1–2% value/income position, not a core or growth holding. A disciplined value buyer would prefer an entry nearer the low-$70s (closer to the 52-week low) for margin of safety, rather than chasing here.
Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-07-21 print (first clean read on synergies). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $78.62.
Single biggest risk: generative AI hollowing out the agency model faster than Omnicom can reposition.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — there is no expert coverage of OMC in the Synthos knowledge base. This verdict is explicitly fundamentals- and quant-driven; no conviction is claimed or fabricated.
Data as-of: fundamentals 2026-03-31 (Q1'26, first full quarter with IPG) · estimates & prices 2026-07-02/03 · SEC 8-K guidance 2026-04-28. Forward figures are analyst consensus (FMP), labeled as estimates.
Data-quality flag: FMP forward per-share EPS estimates appear struck on a pre-IPG (~205M) share count and are overstated vs. the ~299M post-merger diluted base; valuation is therefore anchored on EV/EBITDA, FCF, and the company's own Non-GAAP adjusted EPS, not on those figures (see §6).
Management caveat: the Q1'26 8-K guidance is management's own, self-interested framing (synergies + buyback emphasis), half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").